

ALB/PR

30th January 1990

Dr J A F Napier  
Director  
Regional Blood Transfusion Service  
Rhydlafer  
St Fagans  
CARDIFF

Dear Tony,

Further to our telephone conversation I am writing to confirm our present hierarchy of treatment preferences for haemophilia A.

These are as follows:

1. BPL 8Y - first choice
2. Hemate P (Hoechst)

The Alpha product Profilate which was our previous commercial choice does sometimes transmit Hepatitis and we have only used this on previously exposed patients. However, now that supplies of Hemate P, which is a licensed product are available, I would like to prevent the use of Profilate all together. I do not even like having it in the storage refrigerator in case it is used by junior staff after hours, however, I appreciate that it is too expensive to destroy unless you feel that the budget could meet this.

I understand that there are stocks of 8Y at BPL which are not being taken up and which will shortly expire. This sounds as if our allocation from BPL should be increased, but I feel that Dr Lane should be aware how important it is that he guarantees continuity at any given level of supply. We in turn should then be able to guarantee some purchasing policy with the commercial company. The import of Hemate P for instance into the UK is limited and the material will be supplied to other centres if we cannot offer some reasonable guarantee of use. . I think that it is time now for BPL to market their product in a more organised fashion so that we are all aware of what is available and receive some guarantee of continuity of supply.

2

30th January 1990

On a day to day basis, perhaps Miss Pengally could have a more detailed discussion with Sister Jones and Dr Dasani.

Kindest regards,

Yours sincerely,

A L BLOOM

Copy to:

Internal

Dr H Dasani  
Sister J Jones

116